Systemic sclerosis & Raynaud's

Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression response

Rheumatology (Oxford)Published Cohort study

Authors' conclusion

NSIP and OP were associated with better outcomes and response to immunosuppression, while fHP had worse survival compared with UIP.

Study context

Population
Patients with CTD-ILD (most frequent: SSc n = 215, RA n = 127, inflammatory myopathies n = 100)
Participants
645 patients
Exposure
HRCT imaging patterns vs usual interstitial pneumonia (UIP)
Outcome
Transplant-free survival and change in percent-predicted FVC
Methodological detailsHRCT reviewed by expert radiologists blinded to clinical data, Cox and linear mixed-effects models adjusted for age, sex, smoking and baseline forced vital capacity (FVC)
  • HRCT reviewed by expert radiologists blinded to clinical data
  • Cox and linear mixed-effects models adjusted for age, sex, smoking and baseline FVC

Main finding

As reported in the abstract

Each group vs UIPHazard ratio (mortality) (95% CI)
NSIP
0.65(0.45–0.93)
OP
0.18(0.05–0.57)
fHP
1.58(1.01–2.40)

Slower FVC decline, %/year

Non-specific interstitial pneumonia (NSIP)
1.1 (95% CI 0.2–1.9)
Organizing pneumonia (OP)
3.5 (95% CI 2.0–4.9)

Observational data: associations, not effects.

Further findings

OutcomeSlower FVC decline (%/year) (95% CI)
FVC decline after immunosuppression vs pre-treatment2.1 (1.4–2.8)

Extent of fibrosis

The extent of fibrosis also predicted FVC decline and mortality

FVC decline after immunosuppression vs pre-treatment

No change for UIP or fibrotic hypersensitivity pneumonitis (fHP)

Original publication

Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression response. Rheumatology (Oxford). Published 9 February 2024. doi:10.1093/rheumatology/keae076

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.